Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-18-000396
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-01-02 20:24:20
Reporting Period:
2017-12-28
Accepted Time:
2018-01-02 20:24:20
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
921299 Fibrogen Inc FGEN Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1623238 B Thomas Neff C/o Fibrogen, Inc.
409 Illinois St.
San Francisco CA 94158
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2017-12-15 500 $0.00 3,071,705 No 5 G Direct
Common Stock Disposition 2017-12-15 500 $0.00 19,500 No 5 G Indirect By Spouse
Common Stock Disposition 2017-12-28 18,550 $48.28 3,053,155 No 4 S Direct
Common Stock Disposition 2017-12-28 350 $48.72 3,052,805 No 4 S Direct
Common Stock Disposition 2017-12-28 418 $48.30 127,096 No 4 S Indirect By Family Partnership
Common Stock Disposition 2017-12-29 9,087 $48.06 3,043,718 No 4 S Direct
Common Stock Disposition 2017-12-29 9,813 $48.88 3,033,905 No 4 S Direct
Common Stock Disposition 2017-12-29 418 $48.36 126,678 No 4 S Indirect By Family Partnership
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 5 G Direct
No 5 G Indirect By Spouse
No 4 S Direct
No 4 S Direct
No 4 S Indirect By Family Partnership
No 4 S Direct
No 4 S Direct
No 4 S Indirect By Family Partnership
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 60,946 Indirect See footnote
Footnotes
  1. Shares sold pursuant to a 10b5-1 plan.
  2. The shares were sold at prices ranging from $47.70 to $48.675. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  3. The shares were sold at prices ranging from $48.70 to $48.725. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  4. The shares were sold at prices ranging from $48.00 to $48.30. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  5. The shares were sold at prices ranging from $47.45 to $48.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  6. The shares were sold at prices ranging from $48.45 to $49.20. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  7. The shares were sold at prices ranging from $47.45 to $48.45. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  8. The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.